When Amazon Web Services redefined enterprise computing, it did so not by writing applications but by owning the infrastructure beneath them. NVIDIA appears to be executing a strikingly similar strategy in pharmaceutical AI — and BioNeMo is its platform of record.
Over the past year, NVIDIA's BioNeMo has quietly become the default AI infrastructure layer for a growing cohort of drug discovery and biotech firms. The platform, which provides pre-trained biological foundation models, GPU-accelerated workflows, and APIs for molecular biology and genomics tasks, is now embedded in the R&D pipelines of companies ranging from Big Pharma incumbents to venture-backed startups.
High-Profile Anchors Signal Platform Credibility
The clearest signal of BioNeMo's institutional traction is its adoption by Eli Lilly and Thermo Fisher Scientific — two organizations whose technology choices carry significant downstream influence across the industry. Eli Lilly, which spent $2.5 billion on AI and digital capabilities between 2020 and 2024, is integrating BioNeMo's molecular simulation tools into its early-stage discovery workflows. Thermo Fisher, as a critical instruments and services provider to virtually every major pharma company, represents a multiplier effect: BioNeMo capabilities embedded in Thermo Fisher's platforms reach clients who may never directly license NVIDIA software.
These anchor partnerships are not merely commercial wins — they function as credibility signals that accelerate adoption across the broader ecosystem.
An Ecosystem Is Forming
The more structurally significant development is the proliferation of specialized AI biotech firms building foundation models on top of BioNeMo's infrastructure. Terray Therapeutics and Apheris have both trained proprietary models on BioNeMo, effectively betting that NVIDIA's platform will remain the dominant substrate for biological AI computation. This is the classic platform lock-in dynamic: as more models, tools, and workflows are built atop BioNeMo, switching costs rise for the entire ecosystem.
Firms like Natera, Owkin, and Basecamp Research have launched specialized biotech AI platforms that reflect the same underlying architectural shift — AI-native workflows replacing or augmenting traditional wet-lab processes. Natera's computational genomics capabilities, Owkin's federated learning platform for clinical data, and Basecamp Research's biodiversity-derived protein datasets all represent nodes in an emerging AI-native drug discovery stack.
The Infrastructure Thesis
What makes BioNeMo strategically distinct from a simple software toolkit is its positioning at the model layer rather than the application layer. By providing pre-trained foundation models for protein structure prediction, molecular docking, and genomic sequence analysis, NVIDIA is capturing value at the point where compute and biology intersect — a position that becomes more defensible as biological datasets and training runs grow exponentially more expensive.
The analogy to NVIDIA's dominance in large language model infrastructure is deliberate and apt. Just as CUDA became the de facto programming layer for general AI, BioNeMo is being engineered to become the default for biological AI — with the GPU revenue flowing underneath both.
Investment and M&A Implications
For investors, the BioNeMo ecosystem signals where capital will concentrate. Companies with deep BioNeMo integration are likely acquisition targets for larger pharma firms seeking to internalize AI-native discovery capabilities rather than license them indefinitely. The structural shift from traditional lab processes to AI-native workflows also compresses drug discovery timelines — historically 10-15 years from target identification to clinical candidate — in ways that fundamentally reprice biotech pipeline valuations.
The platform wave is still forming, but the infrastructure layer is already being claimed.